Company
Headquarters: Puning, China
Employees: 7,786
CN¥26.48 Billion
CNY as of July 1, 2025
US$3.70 Billion
| Company | Market Cap (USD) |
|---|---|
| Lilly | $699.59 B |
| Johnson & Johnson | $374.29 B |
| AbbVie | $336.94 B |
| Novo Nordisk | $309.91 B |
| UnitedHealth Group | $279.90 B |
Kangmei Pharmaceutical Co., Ltd. produces and sells Chinese medicines in China. It also offers chemical drug products; and operates hospitals and Chinese medicine pharmacies. The company was founded in 1997 and is headquartered in Puning, China.
| Last Financial Reports Date | March 31, 2025 |
| Revenue TTM | CN¥5.29 B |
| EBITDA | CN¥500.4 M |
| Gross Profit TTM | CN¥715.5 M |
| Profit Margin | 0.18% |
| Operating Margin | 1.14% |
| Quarterly Revenue Growth | 8.20% |
Kangmei Pharmaceutical Co. Ltd has the following listings and related stock indices.
Stock: SSE: 600518 wb_incandescent